About Suven Life Sciences Limited
Data last updated: 15 July 2026
Suven Life Sciences Limited is a public limited company based in Hyderabad, Telangana, India, a subsidiary of Jasti Property And Equity Holdings Private Limited. It specialises in pharma contract r and d, a part of the broader pharmaceuticals sector. Incorporated on 09 March 1989, the company has been in operation for over 37 years.
Registered with ROC Hyderabad under CIN L24110AP1989PLC009713. Listed on BSE: 530239 and NSE: SUVEN.
Capital: an authorised share capital of ₹50 Cr and a paid-up capital of ₹26.4 Cr. Formerly known as Suven Synthesis Ltd and Suven Pharmaceuticals Pvt Ltd. It is led by directors including Santanu Mukherjee and Sudharani Jasti.
Last AGM: 22 August 2025. Financial statements filed for year ended 31 March 2025. Office: Door No. 8 – 2 – 334 6Th Floor Sde Serene Chambers Road No. 5 Avenue 7 Banjara Hills, Hyderabad, Telangana, India – 500034.
As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹7.11 Cr, a growth of 6.89% compared to the previous year. The net worth stands at ₹591.4 Cr (up 437.7% YoY). Total assets are valued at ₹624.21 Cr (up 361.75% YoY).
The company has a workforce of approximately 137 employees as per the latest available data. It operates as a subsidiary of Jasti Property And Equity Holdings Private Limited.
The company is associated with 3 brands - Suven Nishtaa, Suven Life Sciences, Suven Pharma. As per MCA filings, the company has satisfied charges of ₹239.04 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website suven.com.
-
EmailLocked
-
TelephoneLocked
-
WebsiteLocked
-
Social Media
-
Registered AddressDoor No. 8 – 2 – 334 6Th Floor Sde Serene Chambers Road No. 5 Avenue 7 Banjara Hills, Hyderabad, Telangana, India – 500034
-
IndustryPharma, Pharma Contract R&D
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Suven Life Sciences Limited
Suven Life Sciences Limited has undergone 2 name changes throughout its history. The company was previously known as Suven Synthesis Ltd, and Suven Pharmaceuticals Pvt Ltd. The current legal name is Suven Life Sciences Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Suven Life Sciences Limited | Current |
| Suven Synthesis Ltd | Previous |
| Suven Pharmaceuticals Pvt Ltd | Previous |
CIN History of Suven Life Sciences Limited
Suven Life Sciences Limited has one previous CIN (Corporate Identification Number): L24110AP1989PLC009713. The current CIN is L24110TG1989PLC009713, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24110TG1989PLC009713 | Current |
| L24110AP1989PLC009713 | Previous |
Associated Brands with Suven Life Sciences Limited
Suven Life Sciences Limited operates multiple associated brands including Suven Nishtaa, Suven Life Sciences, and Suven Pharma. These brands represent Suven Life Sciences Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Online drug store | suvennishtaa.com | |
| CDMO services and CNS drug discovery pipeline are offered. | suven.com | |
| Contract manufacturing and development of APIs and formulations are provided. | suvenpharm.com |
Competitors & Alternatives of Suven Life Sciences Limited
Brands and companies operating in the same space as Suven Life Sciences Limited include Concord Biotech, BDR Pharmaceuticals Internationals, Almac Group and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Concord Biotech
|
APIs and enzymes are manufactured through fermentation by the CDMO. | Ahmedabad, India, India | 2000 |
BDR Pharmaceuticals Internationals
|
APIs and finished products are developed and manufactured. | Mumbai, India, India | 2003 |
Almac Group
|
Integrated CDMO services for biopharma R&D and manufacturing are offered. | Craigavon, United Kingdom, United Kingdom | 2001 |
Indoco Remedies
|
APIs manufacturing and formulation services are provided in therapeutic segments. | Mumbai, India, India | 1947 |
Pharmaceutics International
|
Pharmaceutical dosage forms are manufactured by this CDMO. | Hunt Valley, United States, United States | 1994 |
Aurobindo Pharma
|
Generic biocatalytic solutions are provided for pharmaceutical applications. | Hyderabad, India, India | 1986 |
Seqens
|
Contract manufacturing services for small molecules and peptides are provided. | Ecully, France, France | 2003 |
Asymchem
|
APIs and peptides are developed and manufactured by Asymchem. | Morrisville, United States, United States | 1995 |
Aptuit
|
Contract research and development services for small molecules are offered. | Greenwich, United States, United States | 2004 |
Continuus Pharma
|
MIT-Novartis spinoff offering continuous manufacturing solutions to remove the proverbial wall between API and FDF manufacturing in small molecule development | Woburn, United States, United States | 2012 |
Business Activity of Suven Life Sciences Limited
Suven Life Sciences Limited is engaged in the principal business activity of professional, scientific and technical, with detailed activities including scientific research and development.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M5 | Scientific research and development | Locked |
Business activity turnover details for Suven Life Sciences Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Suven Life Sciences Limited
Suven Life Sciences Limited is audited by KARVY & Co. (ICAI peer reviewed, certificate valid till 2024-10-31) for the financial year 2025, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| KARVY & Co. (ICAI peer reviewed, certificate valid till 2024-10-31) | FY 2025 | Declaration of unmodified opinion |
Board of Directors of Suven Life Sciences Limited
Suven Life Sciences Limited is currently managed by 6 directors, with 18 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Santanu Mukherjee
Also directs:
Aurobindo Pharma Ltd, Sumedha Fiscal Services Ltd, Rainbow Children's Medicare Limited and 4 more
|
Director | 15 May 2018 | 8 Years 3 Months | Current |
| Sudharani Jasti | Whole-Time Director | 04 Jan 2013 | 13 Years 7 Months | Current |
|
Venkateswarlu Jasti
Also directs:
Svsmk Property Llp, Jasti Property And Equity Holdings Private Limited, Svj Property Holdings Llp and 5 more
|
Managing Director | 04 Jan 2010 | 16 Years 7 Months | Current |
| Vajja Sambasiva Rao | Director | 30 Jan 2024 | 2 Years 6 Months | Current |
| Seyed Ehtesham Hasnain | Director | 30 Apr 2010 | 16 Years 3 Months | Current |
| Ananthasai Padmaja Jasthi | Director | 14 Nov 2018 | 7 Years 9 Months | Current |
Financials of Suven Life Sciences Limited FY 2026 filings available
Suven Life Sciences Limited reported revenue of ₹7.11 Cr (up 6.89% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹7.11 Cr | ₹6.66 Cr | ₹11.69 Cr | ₹13.54 Cr | ₹11.84 Cr | ₹13.48 Cr | ₹14.41 Cr |
| Other Income | ₹13.93 Cr | ₹10.9 Cr | ₹21.13 Cr | ₹8.45 Cr | ₹5.32 Cr | ₹7.75 Cr | ₹14.04 Cr |
| Total Income | ₹21.04 Cr | ₹17.55 Cr | ₹32.82 Cr | ₹21.99 Cr | ₹17.16 Cr | ₹21.23 Cr | ₹28.45 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹24.15 Cr | ₹20.82 Cr | ₹18.99 Cr | ₹18.62 Cr | ₹21.02 Cr | ₹18.53 Cr | ₹17.41 Cr |
| Finance Costs | ₹15.78 Lakh | ₹4.66 Lakh | ₹15.84 Lakh | ₹28.91 Lakh | ₹53.01 Lakh | ₹81.54 Lakh | ₹55.14 Lakh |
| Depreciation & Amortisation | ₹5.61 Cr | ₹5.82 Cr | ₹6.5 Cr | ₹6.54 Cr | ₹4.39 Cr | ₹4.35 Cr | ₹4.17 Cr |
| Other Expenses | ₹267.47 Cr | ₹151.6 Cr | ₹120.71 Cr | ₹120.8 Cr | ₹113.21 Cr | ₹75.02 Cr | ₹112.72 Cr |
| Total Expenses | ₹297.39 Cr | ₹178.3 Cr | ₹146.36 Cr | ₹146.26 Cr | ₹139.16 Cr | ₹98.71 Cr | ₹134.85 Cr |
| Profit Before Exceptional Items & Tax | -₹276.34 Cr | -₹160.75 Cr | -₹113.54 Cr | -₹124.27 Cr | -₹122 Cr | -₹77.47 Cr | -₹106.4 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹7.46 Cr | ₹6 Cr | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹276.34 Cr | -₹160.75 Cr | -₹106.08 Cr | -₹118.27 Cr | -₹122 Cr | -₹77.47 Cr | -₹106.4 Cr |
| Total Tax Expense | ₹0 | ₹0 | -₹1 Cr | ₹0 | ₹0 | -₹5.32 Cr | -₹12.18 Cr |
| Net Profit | -₹276.34 Cr | -₹160.75 Cr | -₹105.08 Cr | -₹118.27 Cr | -₹122 Cr | -₹72.15 Cr | -₹94.22 Cr |
| attributable to Owners | - | - | - | ₹0 | ₹0 | ₹0 | - |
| attributable to NCI | - | - | - | ₹0 | ₹0 | ₹0 | - |
| Other Comprehensive Income | -₹1.18 Cr | -₹58.33 Lakh | -₹6 Lakh | ₹18.99 Lakh | -₹15.05 Lakh | -₹30.67 Lakh | -₹29.54 Lakh |
| Total Comprehensive Income | -₹277.53 Cr | -₹161.33 Cr | -₹105.14 Cr | -₹118.08 Cr | -₹122.15 Cr | -₹72.46 Cr | -₹94.51 Cr |
| EBITDA (computed) | -₹270.57 Cr | -₹154.88 Cr | -₹106.87 Cr | -₹117.44 Cr | -₹117.07 Cr | -₹72.31 Cr | -₹101.68 Cr |
| Basic EPS | ₹-12.13 | ₹-7.37 | ₹-4.82 | ₹-6.63 | ₹-9.57 | ₹-5.67 | ₹-2.01 |
| Diluted EPS | ₹-12.13 | ₹-7.37 | ₹-4.82 | ₹-6.63 | ₹-9.57 | ₹-5.67 | ₹-7.40 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹624.21 Cr | ₹135.18 Cr | ₹284.9 Cr | ₹388.91 Cr |
| Non-current Assets | ₹77.51 Cr | ₹59.71 Cr | ₹28.23 Cr | ₹137.32 Cr |
| Current Assets | ₹546.71 Cr | ₹75.47 Cr | ₹256.67 Cr | ₹251.59 Cr |
| Property, Plant & Equipment | ₹55.7 Cr | ₹59.47 Cr | ₹27.5 Cr | ₹35.73 Cr |
| Inventories | ₹10.2 Lakh | ₹23.75 Lakh | ₹70.85 Lakh | ₹0 |
| Trade Receivables | ₹1.51 Cr | ₹1.34 Cr | ₹1.29 Cr | ₹80.74 Lakh |
| Cash & Equivalents | ₹8.28 Cr | ₹15.03 Cr | ₹14.93 Cr | ₹37.02 Cr |
| Equity (Net Worth) | ₹591.4 Cr | ₹109.99 Cr | ₹270.04 Cr | ₹375.32 Cr |
| Equity Share Capital | ₹26.37 Cr | ₹21.81 Cr | ₹21.81 Cr | ₹21.81 Cr |
| Borrowings (Non-current) | ₹0 | ₹0 | ₹0 | ₹0 |
| Borrowings (Current) | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Debt (computed) | ₹0 | ₹0 | ₹0 | ₹0 |
| Current Liabilities | ₹30.9 Cr | ₹23.49 Cr | ₹13.52 Cr | ₹11.13 Cr |
| Total Liabilities | ₹32.81 Cr | ₹25.2 Cr | ₹14.86 Cr | ₹13.59 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹301.79 Cr | -₹154.1 Cr | -₹82.62 Cr | -₹207.93 Cr | -₹127.54 Cr |
| Investing Cash Flow | -₹462.11 Cr | ₹154.95 Cr | ₹61.59 Cr | -₹155.71 Cr | -₹22.23 Cr |
| Financing Cash Flow | ₹757.15 Cr | -₹75.63 Lakh | -₹1.05 Cr | ₹395.54 Cr | ₹145.69 Cr |
| Capital Expenditure | ₹5.08 Cr | ₹37.28 Cr | -₹2.42 Cr | ₹2.89 Cr | ₹19.77 Cr |
| Free Cash Flow (computed) | -₹306.87 Cr | -₹191.38 Cr | -₹85.04 Cr | -₹210.82 Cr | -₹147.31 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹6.75 Cr | ₹9.31 Lakh | -₹22.09 Cr | ₹31.75 Cr | -₹4.07 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1.52 Cr | ₹2.81 Cr | ₹91.92 Lakh | ₹1.87 Cr | ₹1.47 Cr | ₹1.61 Cr | ₹2.57 Cr | ₹1.01 Cr | ₹2.39 Cr | ₹2.45 Cr | ₹3.06 Cr | ₹3.8 Cr |
| Other Income | ₹6.78 Cr | ₹2.77 Cr | ₹3.78 Cr | ₹59.98 Lakh | ₹1.22 Cr | ₹1.63 Cr | ₹4.04 Cr | ₹4.01 Cr | ₹4.28 Cr | ₹6.07 Cr | ₹5.14 Cr | ₹5.64 Cr |
| Total Income | ₹8.3 Cr | ₹5.58 Cr | ₹4.7 Cr | ₹2.47 Cr | ₹2.69 Cr | ₹3.24 Cr | ₹6.61 Cr | ₹5.01 Cr | ₹6.67 Cr | ₹8.52 Cr | ₹8.2 Cr | ₹9.44 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹5.83 Cr | ₹6.27 Cr | ₹6.08 Cr | ₹5.98 Cr | ₹6.07 Cr | ₹4.87 Cr | ₹5.2 Cr | ₹4.69 Cr | ₹3.46 Cr | ₹5.79 Cr | ₹4.45 Cr | ₹5.28 Cr |
| Finance Costs | ₹15.78 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹79,000 | ₹1.56 Lakh | ₹2.31 Lakh | ₹2.99 Lakh | ₹3.54 Lakh | ₹4.19 Lakh | ₹5.12 Lakh |
| Depreciation & Amortisation | ₹1.58 Cr | ₹1.35 Cr | ₹1.32 Cr | ₹1.37 Cr | ₹1.35 Cr | ₹1.53 Cr | ₹1.46 Cr | ₹1.49 Cr | ₹1.51 Cr | ₹1.6 Cr | ₹1.73 Cr | ₹1.66 Cr |
| Other Expenses | ₹46.32 Cr | ₹99.89 Cr | ₹74.61 Cr | ₹46.64 Cr | ₹39.22 Cr | ₹35.95 Cr | ₹49.58 Cr | ₹26.85 Cr | ₹29.21 Cr | ₹42.85 Cr | ₹22.12 Cr | ₹26.53 Cr |
| Total Expenses | ₹53.89 Cr | ₹107.51 Cr | ₹82.01 Cr | ₹53.98 Cr | ₹46.63 Cr | ₹42.36 Cr | ₹56.25 Cr | ₹33.05 Cr | ₹34.21 Cr | ₹50.28 Cr | ₹28.34 Cr | ₹33.53 Cr |
| Profit Before Exceptional Items & Tax | -₹45.6 Cr | -₹101.92 Cr | -₹77.31 Cr | -₹51.52 Cr | -₹43.94 Cr | -₹39.12 Cr | -₹49.64 Cr | -₹28.04 Cr | -₹27.54 Cr | -₹41.76 Cr | -₹20.14 Cr | -₹24.09 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹7.46 Cr | ₹0 |
| Profit Before Tax | -₹45.6 Cr | -₹101.92 Cr | -₹77.31 Cr | -₹51.52 Cr | -₹43.94 Cr | -₹39.12 Cr | -₹49.64 Cr | -₹28.04 Cr | -₹27.54 Cr | -₹41.76 Cr | -₹12.68 Cr | -₹24.09 Cr |
| Total Tax Expense | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹1 Cr | ₹0 | ₹0 | ₹0 |
| Net Profit | -₹45.6 Cr | -₹101.92 Cr | -₹77.31 Cr | -₹51.52 Cr | -₹43.94 Cr | -₹39.12 Cr | -₹49.64 Cr | -₹28.04 Cr | -₹26.54 Cr | -₹41.76 Cr | -₹12.68 Cr | -₹24.09 Cr |
| attributable to Owners | - | - | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 |
| attributable to NCI | - | - | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 |
| Other Comprehensive Income | -₹46.66 Lakh | -₹75.13 Lakh | ₹8.52 Lakh | -₹5.12 Lakh | -₹56.98 Lakh | -₹45,000 | -₹45,000 | -₹45,000 | -₹20.24 Lakh | ₹4.75 Lakh | ₹4.75 Lakh | ₹4.75 Lakh |
| Total Comprehensive Income | -₹46.06 Cr | -₹102.67 Cr | -₹77.22 Cr | -₹51.57 Cr | -₹44.51 Cr | -₹39.12 Cr | -₹49.65 Cr | -₹28.04 Cr | -₹26.74 Cr | -₹41.72 Cr | -₹12.63 Cr | -₹24.04 Cr |
| EBITDA (computed) | -₹43.86 Cr | -₹100.58 Cr | -₹75.99 Cr | -₹50.15 Cr | -₹42.6 Cr | -₹37.58 Cr | -₹48.17 Cr | -₹26.53 Cr | -₹26 Cr | -₹40.13 Cr | -₹18.37 Cr | -₹22.37 Cr |
| Basic EPS | ₹-2.02 | ₹-4.55 | ₹-3.48 | ₹-2.36 | ₹-2.02 | ₹-1.79 | ₹-2.27 | ₹-1.29 | ₹-1.22 | ₹-1.92 | ₹-0.58 | ₹-1.10 |
| Diluted EPS | ₹-2.02 | ₹-4.55 | ₹-3.48 | ₹-2.36 | ₹-2.02 | ₹-1.79 | ₹-2.27 | ₹-1.29 | ₹-1.22 | ₹-1.92 | ₹-0.58 | ₹-1.10 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹7.11 Cr | ₹6.66 Cr | ₹11.69 Cr | ₹13.54 Cr | ₹11.84 Cr | ₹13.48 Cr | ₹14.41 Cr |
| Other Income | ₹13.91 Cr | ₹10.73 Cr | ₹21.13 Cr | ₹8.45 Cr | ₹5.32 Cr | ₹7.75 Cr | ₹14.04 Cr |
| Total Income | ₹21.03 Cr | ₹17.38 Cr | ₹32.82 Cr | ₹21.99 Cr | ₹17.16 Cr | ₹21.23 Cr | ₹28.45 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹24.15 Cr | ₹20.82 Cr | ₹16.53 Cr | ₹15.77 Cr | ₹17.46 Cr | ₹15.29 Cr | ₹14.6 Cr |
| Finance Costs | ₹15.78 Lakh | ₹4.66 Lakh | ₹15.84 Lakh | ₹28.91 Lakh | ₹53.01 Lakh | ₹81.54 Lakh | ₹54.03 Lakh |
| Depreciation & Amortisation | ₹5.61 Cr | ₹5.82 Cr | ₹6.5 Cr | ₹6.54 Cr | ₹4.39 Cr | ₹4.35 Cr | ₹4.17 Cr |
| Other Expenses | ₹45.97 Cr | ₹37.77 Cr | ₹26.1 Cr | ₹25.51 Cr | ₹31.02 Cr | ₹28.74 Cr | ₹35.08 Cr |
| Total Expenses | ₹75.89 Cr | ₹64.46 Cr | ₹49.29 Cr | ₹48.12 Cr | ₹53.41 Cr | ₹49.19 Cr | ₹54.39 Cr |
| Profit Before Exceptional Items & Tax | -₹54.86 Cr | -₹47.08 Cr | -₹16.47 Cr | -₹26.13 Cr | -₹36.25 Cr | -₹27.95 Cr | -₹25.94 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹7.46 Cr | ₹6 Cr | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹54.86 Cr | -₹47.08 Cr | -₹9.01 Cr | -₹20.13 Cr | -₹36.25 Cr | -₹27.95 Cr | -₹25.94 Cr |
| Total Tax Expense | ₹0 | ₹0 | -₹1 Cr | ₹0 | ₹0 | -₹5.32 Cr | -₹12.18 Cr |
| Net Profit | -₹54.86 Cr | -₹47.08 Cr | -₹8.01 Cr | -₹20.13 Cr | -₹36.25 Cr | -₹22.63 Cr | -₹13.75 Cr |
| Other Comprehensive Income | -₹22.19 Lakh | -₹5.69 Lakh | -₹6 Lakh | ₹18.99 Lakh | -₹15.05 Lakh | -₹30.67 Lakh | -₹29.54 Lakh |
| Total Comprehensive Income | -₹55.08 Cr | -₹47.14 Cr | -₹8.07 Cr | -₹19.94 Cr | -₹36.4 Cr | -₹22.94 Cr | -₹14.05 Cr |
| EBITDA (computed) | -₹49.09 Cr | -₹41.21 Cr | -₹9.81 Cr | -₹19.29 Cr | -₹31.33 Cr | -₹22.79 Cr | -₹21.23 Cr |
| Basic EPS | ₹-2.41 | ₹-2.16 | ₹-0.37 | ₹-1.13 | ₹-2.84 | ₹-1.78 | ₹-1.08 |
| Diluted EPS | ₹-2.41 | ₹-2.16 | ₹-0.37 | ₹-1.13 | ₹-2.84 | ₹-1.78 | ₹-1.08 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹1,531.06 Cr | ₹808.89 Cr | ₹851.48 Cr | ₹860.44 Cr |
| Non-current Assets | ₹990.35 Cr | ₹751.18 Cr | ₹605.34 Cr | ₹619.18 Cr |
| Current Assets | ₹540.71 Cr | ₹57.71 Cr | ₹246.14 Cr | ₹241.26 Cr |
| Property, Plant & Equipment | ₹55.7 Cr | ₹59.47 Cr | ₹27.5 Cr | ₹35.73 Cr |
| Inventories | ₹10.2 Lakh | ₹23.75 Lakh | ₹70.85 Lakh | ₹0 |
| Trade Receivables | ₹1.51 Cr | ₹1.34 Cr | ₹1.29 Cr | ₹80.74 Lakh |
| Cash & Equivalents | ₹2.28 Cr | ₹46.35 Lakh | ₹4.4 Cr | ₹26.7 Cr |
| Equity (Net Worth) | ₹1,503.37 Cr | ₹799.51 Cr | ₹845.38 Cr | ₹853.44 Cr |
| Equity Share Capital | ₹26.37 Cr | ₹21.81 Cr | ₹21.81 Cr | ₹21.81 Cr |
| Borrowings (Non-current) | ₹0 | ₹0 | ₹0 | ₹0 |
| Borrowings (Current) | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Debt (computed) | ₹0 | ₹0 | ₹0 | ₹0 |
| Current Liabilities | ₹3.75 Cr | ₹7.67 Cr | ₹4.76 Cr | ₹4.54 Cr |
| Total Liabilities | ₹27.7 Cr | ₹9.38 Cr | ₹6.11 Cr | ₹7 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹69.6 Cr | -₹47.39 Cr | ₹12.29 Cr | -₹114.87 Cr | -₹36.62 Cr |
| Investing Cash Flow | -₹685.74 Cr | ₹44.21 Cr | -₹33.53 Cr | -₹256.88 Cr | -₹107.46 Cr |
| Financing Cash Flow | ₹757.15 Cr | -₹75.63 Lakh | -₹1.05 Cr | ₹395.54 Cr | ₹145.69 Cr |
| Capital Expenditure | ₹5.08 Cr | ₹37.28 Cr | -₹2.42 Cr | ₹2.89 Cr | ₹19.77 Cr |
| Free Cash Flow (computed) | -₹74.68 Cr | -₹84.67 Cr | ₹9.87 Cr | -₹117.76 Cr | -₹56.39 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | ₹1.82 Cr | -₹3.94 Cr | -₹22.3 Cr | ₹23.79 Cr | ₹1.61 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1.52 Cr | ₹2.81 Cr | ₹91.92 Lakh | ₹1.87 Cr | ₹1.47 Cr | ₹1.61 Cr | ₹2.57 Cr | ₹1.01 Cr | ₹2.39 Cr | ₹2.45 Cr | ₹3.06 Cr | ₹3.8 Cr |
| Other Income | ₹6.78 Cr | ₹2.77 Cr | ₹3.78 Cr | ₹58.9 Lakh | ₹1.19 Cr | ₹1.57 Cr | ₹4.03 Cr | ₹3.93 Cr | ₹4.28 Cr | ₹6.07 Cr | ₹5.14 Cr | ₹5.64 Cr |
| Total Income | ₹8.3 Cr | ₹5.57 Cr | ₹4.7 Cr | ₹2.46 Cr | ₹2.66 Cr | ₹3.18 Cr | ₹6.61 Cr | ₹4.94 Cr | ₹6.67 Cr | ₹8.52 Cr | ₹8.2 Cr | ₹9.44 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹5.83 Cr | ₹6.27 Cr | ₹6.08 Cr | ₹5.98 Cr | ₹6.07 Cr | ₹4.87 Cr | ₹5.2 Cr | ₹4.69 Cr | ₹3.46 Cr | ₹4.32 Cr | ₹4.21 Cr | ₹4.54 Cr |
| Finance Costs | ₹15.78 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹79,000 | ₹1.56 Lakh | ₹2.31 Lakh | ₹2.99 Lakh | ₹3.54 Lakh | ₹4.19 Lakh | ₹5.12 Lakh |
| Depreciation & Amortisation | ₹1.58 Cr | ₹1.35 Cr | ₹1.32 Cr | ₹1.37 Cr | ₹1.35 Cr | ₹1.53 Cr | ₹1.46 Cr | ₹1.49 Cr | ₹1.51 Cr | ₹1.6 Cr | ₹1.73 Cr | ₹1.66 Cr |
| Other Expenses | ₹11.9 Cr | ₹11.43 Cr | ₹12.75 Cr | ₹9.89 Cr | ₹10.32 Cr | ₹10.04 Cr | ₹11.01 Cr | ₹6.4 Cr | ₹5.79 Cr | ₹7.33 Cr | ₹6.92 Cr | ₹6.05 Cr |
| Total Expenses | ₹19.47 Cr | ₹19.05 Cr | ₹20.14 Cr | ₹17.23 Cr | ₹17.73 Cr | ₹16.45 Cr | ₹17.68 Cr | ₹12.6 Cr | ₹10.79 Cr | ₹13.29 Cr | ₹12.9 Cr | ₹12.31 Cr |
| Profit Before Exceptional Items & Tax | -₹11.17 Cr | -₹13.47 Cr | -₹15.45 Cr | -₹14.78 Cr | -₹15.07 Cr | -₹13.27 Cr | -₹11.07 Cr | -₹7.67 Cr | -₹4.13 Cr | -₹4.77 Cr | -₹4.7 Cr | -₹2.87 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹7.46 Cr | ₹0 |
| Profit Before Tax | -₹11.17 Cr | -₹13.47 Cr | -₹15.45 Cr | -₹14.78 Cr | -₹15.07 Cr | -₹13.27 Cr | -₹11.07 Cr | -₹7.67 Cr | -₹4.13 Cr | -₹4.77 Cr | ₹2.76 Cr | -₹2.87 Cr |
| Total Tax Expense | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹1 Cr | ₹0 | ₹0 | ₹0 |
| Net Profit | -₹11.17 Cr | -₹13.47 Cr | -₹15.45 Cr | -₹14.78 Cr | -₹15.07 Cr | -₹13.27 Cr | -₹11.07 Cr | -₹7.67 Cr | -₹3.12 Cr | -₹4.77 Cr | ₹2.76 Cr | -₹2.87 Cr |
| Other Comprehensive Income | -₹22.45 Lakh | ₹3.26 Lakh | -₹1.5 Lakh | -₹1.5 Lakh | -₹4.64 Lakh | -₹45,000 | -₹45,000 | -₹45,000 | -₹20.24 Lakh | ₹4.75 Lakh | ₹4.74 Lakh | ₹4.75 Lakh |
| Total Comprehensive Income | -₹11.39 Cr | -₹13.44 Cr | -₹15.46 Cr | -₹14.79 Cr | -₹15.12 Cr | -₹13.28 Cr | -₹11.08 Cr | -₹7.67 Cr | -₹3.33 Cr | -₹4.72 Cr | ₹2.8 Cr | -₹2.82 Cr |
| EBITDA (computed) | -₹9.43 Cr | -₹12.13 Cr | -₹14.13 Cr | -₹13.41 Cr | -₹13.72 Cr | -₹11.73 Cr | -₹9.6 Cr | -₹6.16 Cr | -₹2.59 Cr | -₹3.13 Cr | -₹2.93 Cr | -₹1.15 Cr |
| Basic EPS | ₹-0.50 | ₹-0.60 | ₹-0.70 | ₹-0.68 | ₹-0.69 | ₹-0.61 | ₹-0.51 | ₹-0.35 | ₹-0.14 | ₹-0.22 | ₹0.13 | ₹-0.13 |
| Diluted EPS | ₹-0.50 | ₹-0.60 | ₹-0.70 | ₹-0.68 | ₹-0.69 | ₹-0.61 | ₹-0.51 | ₹-0.35 | ₹-0.14 | ₹-0.22 | ₹0.13 | ₹-0.13 |
Board & Governance of Suven Life Sciences Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Suven Life Sciences Limited has 6 directors - 3 independent and 2 executive. The board is chaired by VENKATESWARLU JASTI.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| VENKATESWARLU JASTI | Executive Director · MD · Chairperson | 1989-03-09 | 2 |
| SUDHARANI JASTI | Executive Director | 1989-03-09 | 1 |
| SEYED EHTESHAM HASNAIN | Non-Executive - Non Independent Director | 2010-04-30 | 1 |
| SANTANU MUKHERJEE | Non-Executive - Independent Director | 2018-05-15 | 4 |
| ANANTHASAI PADMAJA JASTHI | Non-Executive - Independent Director | 2018-11-14 | 1 |
| VAJJA SAMBASIVA RAO | Non-Executive - Independent Director | 2024-01-30 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | SANTANU MUKHERJEE (Chairperson), ANANTHASAI PADMAJA JASTHI, VAJJA SAMBASIVA RAO |
| Nomination and remuneration committee | SANTANU MUKHERJEE (Chairperson), SEYED EHTESHAM HASNAIN, ANANTHASAI PADMAJA JASTHI, VAJJA SAMBASIVA RAO |
| Stakeholders Relationship Committee | VAJJA SAMBASIVA RAO (Chairperson), ANANTHASAI PADMAJA JASTHI, VENKATESWARLU JASTI |
| Risk Management Committee | VENKATESWARLU JASTI (Chairperson), SANTANU MUKHERJEE, VAJJA SAMBASIVA RAO, MOHANKUMAR MALLARAPU |
| Corporate Social Responsibility Committee | VAJJA SAMBASIVA RAO (Chairperson), SEYED EHTESHAM HASNAIN, VENKATESWARLU JASTI |
Charges & Borrowings of Suven Life Sciences Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Dec 2012 | Bank of Bahrain and Kuwait Bsc | ₹6 Cr | Satisfied |
| 24 Aug 2012 | Bank of Bahrain and Kuwait Bsc | ₹30 Cr | Satisfied |
| 17 Feb 2011 | Bank of India | ₹22.63 Cr | Satisfied |
| 14 Jul 2010 | State of Bank Patiala | ₹20 Cr | Satisfied |
| 30 Aug 2007 | State Bank of India | ₹25.35 Cr | Satisfied |
Total charge records: 14 View all charges
Employees and EPFO Compliance at Suven Life Sciences Limited
View historical data on people associated with Suven Life Sciences Limited, including employment history and EPFO contributions.
Employee and EPFO history for Suven Life Sciences Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Suven Life Sciences Limited
GST registrations and filing compliance for Suven Life Sciences Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Suven Life Sciences Limited
Credit ratings, litigation, and regulatory alerts for Suven Life Sciences Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Suven Life Sciences Limited
MSME payment history for Suven Life Sciences Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Suven Life Sciences Limited
Corporate group structure for Suven Life Sciences Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Suven Life Sciences Limited
MCA filings and documents for Suven Life Sciences Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Suven Life Sciences Limited
Recent News on Suven Life Sciences Limited
Frequently Asked Questions about Suven Life Sciences Limited
Suven Life Sciences Limited is an active public limited company in the pharma sector based in Hyderabad, Telangana, India. It was incorporated on 09 March 1989 (37+ years old) and is registered under CIN L24110TG1989PLC009713. Listed on BSE: 530239 and NSE: SUVEN. The company has 137 employees.
Suven Life Sciences Limited reported revenue of ₹7.11 Cr for FY 2026 (up 6.89% YoY) based on consolidated NSE filings.
The current directors of Suven Life Sciences Limited are:
- Santanu Mukherjee - Director
- Sudharani Jasti - Whole-Time Director
- Venkateswarlu Jasti - Managing Director
- Vajja Sambasiva Rao - Director
- Seyed Ehtesham Hasnain - Director
- Ananthasai Padmaja Jasthi - Director
The primary industry of Suven Life Sciences Limited is pharma. The company specifically operates in pharma contract r and d. The company is currently active in this sector.
Yes. Suven Life Sciences Limited is listed on both BSE (code: 530239) and NSE (symbol: SUVEN).
Suven Life Sciences Limited can be reached at the registered office: Door No. 8 – 2 – 334 6Th Floor Sde Serene Chambers Road No. 5 Avenue 7 Banjara Hills, Hyderabad, Telangana, India – 500034, or through the website suven.com.